New therapies in common ocular surface disorders.
Lacrimal dysfunction syndrome (LDS) and meibomian gland dysfunction (MGD) are common pathologies of the ocular surface both characterized by quantitative and/or qualitative tear film changings. They may result in symptoms of eye irritation, clinically apparent inflammation and ocular surface disease. Recent researches about the chronic inflammatory nature of dry eye, revealed the possibility to develop new treatments for LDS like new immunological drugs. MGD, alone or if it occurs contemporary to LDS, can be treated with a thermal pulsation system, a useful tool to alleviate symptoms.
Departments of Cardiovascular, Respiratory, Nephrologic, Anesthesiologic and Geriatric Sciences, Faculty of Medicine and Dentistry, "Sapienza" University of Rome, Italy.
N
N
Pescosolido
F
F
Parisi
G
G
Buomprisco
A
A
Librando
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D004847:Epithelial Cells / Q000473:pathology; D005141:Eyelid Diseases / Q000188:drug therapy / Q000628:therapy*; D006358:Hot Temperature / Q000627:therapeutic use; D006801:Humans; D007638:Keratoconjunctivitis Sicca / Q000209:etiology / Q000503:physiopathology / Q000628:therapy; D007766:Lacrimal Apparatus Diseases / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D050356:Lipid Metabolism; D008537:Meibomian Glands / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology*; D009883:Ophthalmic Solutions / Q000627:therapeutic use; D009994:Osmolar Concentration; D011312:Pressure; D044967:Serum; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D013666:Tears / Q000378:metabolism; D035703:Therapies, Investigational
D000893:Anti-Inflammatory Agents; D009883:Ophthalmic Solutions